Cargando…

Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study

BACKGROUND: Recent trends in vitamin K antagonists (VKA) use in non-valvular atrial fibrillation (NVAF) are useful to evaluate the potential improvement in management of NVAF since the introduction of new oral anticoagulants. Our objective was therefore to describe the contemporary VKA treatment pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renoux, Christel, Coulombe, Janie, Suissa, Samy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862088/ https://www.ncbi.nlm.nih.gov/pubmed/27160254 http://dx.doi.org/10.1186/s12872-016-0269-4

Ejemplares similares

Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study
por: Loo, Simone Y, et al.
Publicado: (2018)

Incidence, Mortality, and Sex Differences of Non‐Valvular Atrial Fibrillation: A Population‐Based Study
por: Renoux, Christel, et al.
Publicado: (2014)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey
por: Gattellari, Melina, et al.
Publicado: (2008)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
por: Berger, Jeffrey S., et al.
Publicado: (2023)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso
por: Yameogo, Aristide Relwendé, et al.
Publicado: (2016)

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
por: Gilligan, Adrienne M., et al.
Publicado: (2017)

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2014)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation
por: Kim, Hyue Mee, et al.
Publicado: (2019)

A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case–control study
por: Azoulay, Laurent, et al.
Publicado: (2012)

Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease
por: Wilson, Lauren E., et al.
Publicado: (2019)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
por: Cases, Aleix, et al.
Publicado: (2021)

Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
por: Oh, Seil, et al.
Publicado: (2018)

Correction: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Publicado: (2019)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
por: Levy, Pierre, et al.
Publicado: (2019)

Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases
por: Huiart, Laetitia, et al.
Publicado: (2018)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
por: Toyoda, Kazunori, et al.
Publicado: (2015)

National Physician Survey for Nonvalvular Atrial Fibrillation (NVAF) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs
por: Saeed, Haseeb, et al.
Publicado: (2020)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients
por: Mincu, Raluca Ileana, et al.
Publicado: (2019)

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
por: Zhao, Shujuan, et al.
Publicado: (2020)

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
por: Zulkifly, Hanis H., et al.
Publicado: (2023)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with non‐valvular atrial fibrillation: A nationwide, population‐based study in Korea
por: Han, Seongwook, et al.
Publicado: (2021)

Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
por: Berger, Jeffrey S., et al.
Publicado: (2021)

Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea
por: Bae, Hee-Joon, et al.
Publicado: (2018)

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
por: Pan, Kuo‐Li, et al.
Publicado: (2017)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Estimating individualized treatment rules in longitudinal studies with covariate-driven observation times
por: Coulombe, Janie, et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
por: Fanaroff, Alexander C, et al.
Publicado: (2022)

Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation
por: Silva Cunha, Pedro, et al.
Publicado: (2022)

Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany — A retrospective cohort study()
por: Bonnemeier, Hendrik, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9s38vfuejmt0a6om9mdjaotb54